

Supplemental Information

YTHDF1 Facilitates the Progression of Hepatocellular Carcinoma by Promoting FZD5 mRNA Translation in an m6A-Dependent Manner

Xiangxiang Liu, Jian Qin, Tianyi Gao, Chenmeng Li, Bangshun He, Bei Pan, Xueni Xu, Xiaoxiang Chen, Kaixuan Zeng, Mu Xu, Chengbin Zhu, Yuqin Pan, Huiling Sun, Li Sun, Tao Xu, and Shukui Wang

Fig. S1 YTHDF1 is upregulated in HCC and associated with prognosis of patients, related to Figure 1. **a** H-score of YTHDF1 in HCC tissues and ANTs. **b** Detection of YTHDF1 protein levels in HCC cell lines and LO2 cells by western blot. **c** Kaplan-Meier survival curves of OS, RFS, PFS, and DSS of HCC patients based on YTHDF1 expression in Kaplan-Meier Plotter database.




Fig. S2 c-MYC and USF1 promote YTHDF1 expression, related to Figure 2. **a** qRT-PCR analysis of the effect of transfecting c-MYC and USF1 overexpression vectors in HepG2 and MHCC-LM3 cells. **b** qRT-PCR analysis of inhibitory effect of si-c-MYC and si-USF1 in HepG2 and MHCC-LM3 cells. **c** c-MYC/MAX and USF1 expression was positively correlated with YTHDF1 expression in HCC based on TCGA database.




Table S1: The correlations between YTHDF1 expression and clinical characteristics of HCC patients ($n = 84$).

Clinicopathologic parameters	Number	YTHDF1 expression		P value
		High	Low	
Gender				
Male	53	28	25	
Female	31	14	17	0.65
Age (years)				
≥60	47	24	23	
<60	37	18	19	0.91
HBV surface antigen				
Negative	27	12	15	
Positive	57	30	27	0.61
Cirrhosis				
Absent	27	11	16	
Present	57	31	26	0.36
Tumor size (cm)				
≥5	45	28	17	
<5	39	14	25	0.028
Differentiation				
High + moderate	41	19	22	
Low	43	23	20	0.67
TNM stage				
I+II	65	27	36	
III+IV	19	15	6	0.042
Barcelona stage				
A+B	60	26	34	
C+D	24	16	8	0.09
Microvascular invasion				
Absent	40	14	26	
Present	44	28	16	0.016

Table S2: RNA sequences used in this study.

Name	Sequence (5'- 3')	Application
si-myc#1	GCGAGGATATCTGGAAGAA	siRNA target site
si-myc#2	CGATGTTGTTCTGTGGAA	siRNA target site
si-myc#3	GGCGAACACACAAACGUCUU	siRNA target site
si-USF1#1	GCTGGACAATGACGTGCTT	siRNA target site
si-USF1#2	GACGACTCGGGATGAGAAA	siRNA target site
si-USF1#3	CGCCGAGACAAGATCAACA	siRNA target site
si-METTL3#1	GCACTTGGATCTACGGAAT	siRNA target site
si-METTL3#2	CGACTACAGTAGCTGCCTT	siRNA target site
si-METTL3#3	CAGTGGATCTGTTGTGATA	siRNA target site
sh-YTHDF1	CGAAAGAGTTGAGTGGAA	shRNA target site
sg-YTHDF1	CACGCCAACGTGACTTCCC	CRISPR/dcas9 target site

Table S3: Primer sequences used in this study.

Name	Sequence (5'-3')	Application
YTHDF1- forward	GACATTGGCACCTGGGATA	qRT-PCR
YTHDF1-Reverse	GCTCTGATACTGCGGTTGAG	qRT-PCR
FZD5- forward	GTCACACCCGCTCTACAACA	qRT-PCR
FZD5-Reverse	GGACGTGGAGATGAAGCACA	qRT-PCR
USF1- forward	GTGATCCAGGGTGCTTCAC	qRT-PCR
USF1-Reverse	CCTCTGAGCCCTGGGTAGTA	qRT-PCR
c-MYC- forward	CCACGAAACTTGCCTCATAG	qRT-PCR
c-MYC-Reverse	TGCAAGGAGAGCCTTCAGAG	qRT-PCR
METTL3- forward	CTATCTCCTGGCACTCGCAAGA	qRT-PCR
METTL3-Reverse	GCTTGAACCGTGCAACCACATC	qRT-PCR
GAPDH- forward	GAACGGGAAGCTCACTGG	qRT-PCR
GAPDH-Reverse	GCCTGCTTCACCACCTTCT	qRT-PCR
FZD5 m6A- forward	GGCGCTGAGCTCCGTGGAC	MeRIP-qRT-PCR
FZD5 m6A -Reverse	CGGCGCGTCGCTCAATCC	MeRIP-qRT-PCR
YTHDF1 promoter- forward 1	CGCGACCTGGAACACGC	ChIP-qRT-PCR
YTHDF1 promoter- Reverse 1	AGGTCCGAAGACTAACACGC	ChIP-qRT-PCR
YTHDF1 promoter- forward 2	TGTGTGGCGGGCTGTA	ChIP-qRT-PCR
YTHDF1 promoter- Reverse 2	TCCCAGTCTCGTGCAGG	ChIP-qRT-PCR

Table S4: Antibodies used in this study.

Antibody	Company	Application	Concentration
YTHDF1	Proteintech (17479-1-AP)	WB	1:1000
		IHC	1:100
		RIP	2.0 µg
FZD5	Abcam (ab75234)	WB	1:500
		IHC	4.0 µg
c-MYC	Proteintech (10828-1-AP)	WB	1:2000
		ChIP	2.0 µg
	Abcam (ab32072)	IHC	1:100
USF1	SANTA CRUZ (sc-390027)	IHC	1:50
		ChIP	2.0
β-catenin	Proteintech (51067-2-AP)	WB	1:2000
		IHC	1:1000
GAPDH	Proteintech (60004-1-Ig)	WB	1:5000
β-actin	Proteintech (60008-1-Ig)	WB	1:5000
HRP-conjugated Affinipure Goat Anti-Mouse IgG(H+L)	Proteintech (SA00001-1)	WB	1:10000
HRP-conjugated Affinipure Goat Anti-Rabbit IgG(H+L)	Proteintech (SA00001-2)	WB	1:10000